What ferritin and transferrin saturation cut‑offs should be used when interpreting an iron panel in adults with chronic kidney disease, including patients on dialysis?

Iron Panel Cutoffs for CKD

In adults with chronic kidney disease, maintain transferrin saturation (TSAT) ≥20% and serum ferritin ≥100 ng/mL for predialysis and peritoneal dialysis patients, or ≥200 ng/mL for hemodialysis patients to define adequate iron status and guide supplementation. 1, 2

Defining Iron Deficiency in CKD

The interpretation of iron panels differs fundamentally between CKD patients and those with normal renal function. Absolute iron deficiency in CKD is defined as:

• TSAT ≤20% AND
• Ferritin ≤100 ng/mL (predialysis and peritoneal dialysis patients) 1, 2, 3
• Ferritin ≤200 ng/mL (hemodialysis patients) 2, 3

Functional iron deficiency occurs when TSAT ≤20% despite ferritin levels above these thresholds, indicating adequate iron stores but insufficient iron availability for erythropoiesis—commonly seen with erythropoiesis-stimulating agent (ESA) therapy 1.

Target Thresholds for Treatment

The NKF-K/DOQI guidelines establish clear targets: maintain TSAT ≥20% and ferritin ≥100 ng/mL in all CKD patients to support hemoglobin goals of 11-12 g/dL 1. These thresholds represent minimum acceptable levels, not optimal targets.

Upper Safety Limits

Withhold IV iron when:

• TSAT >50% OR
• Ferritin >800 ng/mL 1

These upper limits prevent iron overload while acknowledging that most patients achieve adequate hemoglobin with values below these thresholds 1.

Critical Nuances in Interpretation

The TSAT Priority

Recent evidence suggests TSAT <20% carries greater prognostic significance than ferritin levels alone. A 2018 study demonstrated that TSAT <10% independently predicted all-cause mortality (HR 2.83), cardiovascular mortality (HR 4.15), and anemia development (HR 3.07) in CKD patients, regardless of ferritin level 4. A 2024 Korean cohort study confirmed that TSAT <25% independently increased all-cause mortality risk (HR 1.44) in non-dialysis CKD patients 5.

Clinical implication: When TSAT is low (<20%), consider iron supplementation even if ferritin appears adequate, particularly in ESA-treated patients who may have functional iron deficiency 1.

Ferritin as an Acute Phase Reactant

Ferritin increases with inflammation, potentially masking true iron deficiency 1. When ferritin is 100-700 ng/mL with TSAT <20%, distinguish between:

• Functional iron deficiency: Serial ferritin levels decrease during ESA therapy but remain >100 ng/mL
• Inflammatory iron block: Abrupt ferritin increase with sudden TSAT drop

Management approach: Administer weekly IV iron (50-125 mg) for 8-10 doses. If no erythropoietic response occurs, suspect inflammatory block and withhold further iron until inflammation resolves 1.

Monitoring Frequency

During ESA therapy:

• Check TSAT and ferritin at least every 3 months once target hemoglobin achieved 1
• Check monthly during ESA initiation or dose escalation in non-IV iron patients 1

Without ESA therapy:

• Check every 3-6 months if TSAT <20% and ferritin <100 ng/mL 1

Dialysis-Specific Considerations

Hemodialysis patients have higher iron losses (dialyzer blood losses, phlebotomy) requiring:

• Higher ferritin threshold (≤200 ng/mL defines deficiency) 2, 3
• Regular IV iron supplementation (most cannot maintain adequate stores with oral iron alone) 1
• More frequent monitoring given repetitive blood losses 1

Common Pitfalls to Avoid

1. Using general population cutoffs: The ferritin <12 ng/mL and TSAT <16% thresholds for healthy individuals do not apply to CKD 1

2. Relying solely on ferritin: Ferritin >100 ng/mL does not exclude functional iron deficiency if TSAT remains <20% 1

3. Ignoring timing after IV iron: Wait 2 weeks after large IV iron doses (≥1000 mg) before reassessing iron parameters; 7+ days after 200-500 mg doses 1

4. Overlooking inflammation: Elevated CRP with borderline ferritin suggests inflammation may be falsely elevating ferritin levels 6

Emerging Considerations

While the 2012 KDIGO guidelines suggested higher thresholds (ferritin ≤500 ng/mL, TSAT ≤30%) for initiating iron trials 7, long-term safety of maintaining such high iron levels remains unconfirmed 8. The more conservative NKF-K/DOQI targets (TSAT ≥20%, ferritin ≥100-200 ng/mL) represent decades of clinical experience and remain the safest approach until definitive outcome trials establish otherwise 8.

The 2026 KDIGO update emphasizes individualized treatment timing and comprehensive anemia evaluation beyond just iron parameters 9, but the fundamental TSAT ≥20% and ferritin ≥100-200 ng/mL thresholds remain clinically relevant benchmarks for iron adequacy.